SCHEMBL15517367

SCHEMBL15517367

CCOC(=O)c1cc([Si](C)(C)C)nn1-c1cccc(CCl)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
POLB P06746 3/20 0.44
LMNA P02545 2/20 0.44
SCN9A Q15858 1/20 0.43
SMN1; SMN2 Q16637 7/20 0.43
KMT2A Q03164 3/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
PDE4D Q08499 2/20 0.40
PDE4B Q07343 1/20 0.40
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
MCL1 Q07820 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15519989 0.90 ALDH1A1 (0.45) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL19750044 0.86 ALDH1A1 (0.45) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15517248 0.86 ALDH1A1 (0.42) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15517487 0.84 ALDH1A1 (0.48) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15516042 0.83 GRN (0.49) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL20015660 0.81 SCN9A (0.42) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL20028223 0.79 KMT2A (0.53) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15519124 0.78 ALDH1A1 (0.52) ALDH1A1POLBLMNASMN1; SMN2KMT2A
SCHEMBL20028218 0.78 KMT2A (0.52) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL20027770 0.78 KMT2A (0.52) ALDH1A1POLBLMNASCN9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796742-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-24 US disclosed
EP-2890460-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2017-02-22 EP disclosed
US-20160340375-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-11-24 US disclosed
US-20150210722-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2015-07-30 US disclosed
EP-2890460-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-07-08 EP disclosed
WO-2014033446-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210722-A1 KINASE INHIBITORS SYK, SRC, LYN ALDH1A1 2702/4885POLB 3918/4885LMNA 2738/4885
US-20160340375-A1 KINASE INHIBITORS SYK, LYN, BTK ALDH1A1 2639/4885POLB 3978/4885LMNA 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.